Carolyn Bertozzi, PhD, Professor, Department of Chemistry, Stanford University

Research Description: Prof. Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on developing new therapeutic modalities that target disease-related glycobiology. She founded the field of bioorthogonal chemistry, for which she shared the 2022 Nobel Prize in Chemistry. Her group has invented targeted enzyme therapeutics for immune oncology, Lysosome Targeting Chimeras (LYTACs) for extracellular targeted protein degradation, antibody-lectin chimeras (AbLecs) for therapeutic applications, and site-specific bioconjugation methods for synthesis of next-gen antibody-drug conjugates. Her lab has also developed glycoproteomics technologies for disease biomarker discovery, point-of-care diagnostics for tuberculosis, and ultrasensitive antibody detection methods that are being used to diagnose early onset diabetes and viral infections. The Bertozzi Lab collaborates extensively with many members of the NORC.